Penn State Cancer Institute

The trials here

What the 20 trials at this site are about, from their registry records.

Conditions

• Lung cancer7 trials
• Prostate cancer3 trials
• Kidney cancer2 trials
• Melanoma2 trials
• Metastatic breast cancer2 trials
• Pancreatic cancer2 trials
• Childhood cancers1 trial
• Colorectal cancer1 trial
• Endometrial cancer1 trial
• Gastric and oesophageal cancer1 trial
• Head and neck cancer1 trial
• Liver and biliary tract cancer1 trial
• and 3 more

Phase

• Phase 27 trials
• Phase 13 trials
• Phase 1/23 trials
• Phase 33 trials
• Early phase 11 trial

Status

• Completed8 trials
• Active, not recruiting6 trials
• Recruiting4 trials
• Enrolling by invitation1 trial
• Not yet recruiting1 trial

Lead sponsor

• Milton S. Hershey Medical Center6 trials
• Greg Durm, MD2 trials
• PrECOG, LLC.2 trials
• Ajjai Alva, MD1 trial
• Brian Rini1 trial
• and 8 more

Running trials

• Not yet recruiting

  Tirzepatide and Levonorgestrel IUD Therapy for EIN and Early-Stage Endometrial Cancer

  NCT07812636· Early phase 1· Milton S. Hershey Medical Center· Source

  Contact: Shaina Bruce

• Recruiting

  A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)

  NCT07188896· Phase 2· Brian Rini· Source

  Contact: Meredith Belga, RN

• Recruiting

  Safety and Efficacy of AGN-INM176 in Prostate Patients With Rising PSA

  NCT06600698· Phase 1/2· Milton S. Hershey Medical Center· Source

  Contact: Monika Joshi, MD

• Enrolling by invitation

  Clinical Trial to Treat Stage IV Cancer Patients

  NCT06674538· Phase 1· Moonshot Antibodies· Source

• Active, not recruiting

  Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

  NCT05840211· Phase 3· Gilead Sciences· Source

• Active, not recruiting

  Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer

  NCT04762979· Phase 2· Marina N Sharifi· Source

• Active, not recruiting

  Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA)

  NCT04367311· Phase 2· Nasser Hanna· Source

• Recruiting

  Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm

  NCT04317534· Phase 2· Greg Durm, MD· Source

  Contact: Barbara Husic

• Active, not recruiting

  Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC

  NCT04227028· Phase 1· City of Hope Medical Center· Source

• Recruiting

  Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients

  NCT03567889· Phase 3· Philogen S.p.A.· Source

  Contact: Joseph Drabick

• Active, not recruiting

  Ribociclib and Bicalutamide in AR+ TNBC

  NCT03090165· Phase 1/2· Kari Wisinski· Source

• Active, not recruiting

  Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer

  NCT03308396· Phase 1/2· Ajjai Alva, MD· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Endometrial cancer1 recruiting
• Kidney cancer1 recruiting
• Lung cancer1 recruiting
• Melanoma1 recruiting
• Prostate cancer1 recruiting

Closed trials

• Completed

  Using an End-of-life Conversation Game to Engage Patients With Cancer in Advance Care Planning: Phase 2

  NCT06384417· Milton S. Hershey Medical Center· Source

• Completed

  Rectal Spacer for Prostate Cancer Radiation Image Guidance

  NCT05650021· Milton S. Hershey Medical Center· Source

• Completed

  Using an End-of-life Conversation Game to Engage Patients With Cancer in Advance Care Planning

  NCT06028152· Milton S. Hershey Medical Center· Source

• Completed

  AGN-Cogni.Q Acute Dose Safety and Pharmacokinetics Dose-Response in Prostate Cancer Patients

  NCT05375539· Phase 1· Milton S. Hershey Medical Center· Source

• Completed

  DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma

  NCT04334759· Phase 3· PrECOG, LLC.· Source

• Completed

  Liposomal Irinotecan in Combination With Oxaliplatin, Leucovorin, and 5-fluorouracil for Patients With Locally Advanced Pancreatic Carcinoma:

  NCT03861702· Phase 2· Nelson Yee· Source

• Completed

  Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age

  NCT03834688· Phase 2· PrECOG, LLC.· Source

• Completed

  Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)

  NCT03285321· Phase 2· Greg Durm, MD· Source